Date: 2014-09-30
Type of information: Collaboration agreement
Compound: GLX1112
Company: Glialogix (USA - CA) National Multiple Sclerosis Society (USA)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Type agreement: collaboration
Action mechanism: GLX1112 is an improved proprietary formulation of an existing drug that is FDA-approved for non-neurological indications. Glialogix\'s formulation is designed to optimize the PK properties of the parent compound and increase the therapeutic index when used for central nervous system indications.
Disease: multiple sclerosis
Details: * On September 30, 2014, Glialogix, a San Francisco Bay Area-based emerging biopharma company,announced that it has entered into a Sponsored Research Agreement with Fast Forward, a nonprofit organization established by the National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Through this agreement, Fast Forward will provide funding to Glialogix for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS. Supporting the research and development of therapies that reduce the accumulation of disability in progressive MS and restore neuronal function is a key priority of the National MS Society\'s research campaign. The research to be funded by Fast Forward will include advanced pharmacokinetic testing, preclinical models and further mechanistic studies of GLX1112.
Financial terms:
Latest news:
